Akin

Description

Akin Expectorant Formula is presented in a 118 ml dosage form. The product is identified as AKIN Cough Formula.

Uses and Indications

This drug is indicated for the facilitation of mucus clearance in patients with respiratory conditions. It helps to loosen phlegm and thin bronchial secretions, thereby making coughs more productive.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 12 years and over, the recommended dosage is 10 to 20 ml (equivalent to 2 to 4 teaspoonfuls) administered every 4 hours, or as directed by a healthcare professional.

It is important to note that the medication is not indicated for use in children under 12 years of age.

The maximum allowable dosage should not exceed 6 doses within a 24-hour period to avoid potential overdose. Healthcare professionals should ensure that patients adhere to these guidelines to promote safe and effective use of the medication.

Contraindications

Use is contraindicated in the following situations:

• The product should be kept out of the reach of children to prevent accidental ingestion.

• In the event of an overdose, immediate medical assistance or contact with a Poison Control Center is required.

• Discontinue use if cough persists for more than one week, recurs, or is accompanied by fever, rash, or persistent headache; consultation with a healthcare professional is advised.

Warnings and Precautions

Patients should not use this product for the treatment of persistent or chronic coughs associated with smoking, asthma, chronic bronchitis, or emphysema, nor in cases where the cough is accompanied by excessive phlegm (mucus), unless specifically directed by a healthcare professional.

In the event of an overdose, it is imperative to seek medical assistance immediately or contact a Poison Control Center for guidance.

Healthcare professionals should advise patients to discontinue use and consult a physician if the cough persists for more than one week, recurs, or is accompanied by symptoms such as fever, rash, or a persistent headache. A persistent cough may indicate an underlying serious condition that requires further evaluation.

Side Effects

Patients should be aware of the potential adverse reactions associated with this product. It is important to note that this product is not intended for use in cases of persistent or chronic cough, such as those resulting from smoking, asthma, chronic bronchitis, or emphysema, unless directed by a healthcare professional.

In clinical practice, if a cough persists for more than one week, tends to recur, or is accompanied by additional symptoms such as fever, rash, or persistent headache, patients are advised to consult a doctor. A persistent cough may indicate an underlying serious condition that requires medical evaluation.

These warnings highlight the necessity for careful consideration and monitoring of symptoms while using this product to ensure patient safety and appropriate management of any adverse reactions.

Drug Interactions

No specific drug interactions have been identified in the available data. Additionally, there are no reported interactions between the drug and laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the current information.

Packaging & NDC

Below are the non-prescription pack sizes of Akin (guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this medication. Safety and efficacy have not been established in this age group, and therefore, it is contraindicated for children in this category.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Additionally, specific antidotes or treatments may be indicated based on the substance involved, and healthcare professionals should refer to established guidelines or toxicology resources for further management strategies. Continuous monitoring of vital signs and laboratory parameters is recommended to assess the patient's condition and guide further interventions.

In summary, while no specific overdosage information is available, healthcare professionals should remain vigilant and prepared to implement standard overdose management protocols.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center in the event of an overdose. It is crucial for patients to understand the importance of timely intervention in such situations.

Additionally, patients should be informed that if their cough persists for more than one week, tends to recur, or is accompanied by symptoms such as fever, rash, or a persistent headache, they should consult a doctor. A persistent cough may indicate a serious underlying condition, and early medical evaluation is essential for appropriate management.

Storage and Handling

The product is supplied in configurations that include specific NDC numbers, which are essential for identification and inventory management. It should be stored at room temperature, within a temperature range of 15° to 30°C (59° to 86°F).

Healthcare professionals are advised to ensure that the product is not used if the seal under the cap is torn, broken, or missing, as this may compromise the integrity of the product. Proper handling and storage conditions are crucial to maintain the product's efficacy and safety.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Akin, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)